Novo Nordisk $69m Plant Conversion For New Diabetes Drug

- Last updated on GMT

Related tags: Novo nordisk

Novo Nordisk $69m Plant Conversion For New Diabetes Drug
Novo Nordisk says the $69 investment in its Danish plant will convert capacity ready for its new GLP-1 analogue and is a further commitment to Danish manufacturing.

Planned to be operational by the first quarter of 2014, the DK380m plant conversion will, according to the company, create 50 new jobs at the Kalundborg facility, adding to the current workforce of over 2,400 people.

In a statement, Per Valstorp, Senior VP of Product Supply said “the Kalundborg investment reaffirms our long-term commitment to creating and maintaining jobs in Denmark.”

The Danish drugmaker has previously invested over DK7.5bn ($1.3bn) which manufactures amongst other things active pharmaceutical products (APIs) and finished products for Novo Nordisk’s diabetes drugs.

This new investment will convert existing manufacturing capacity ready for future production of the company’s latest GLP-1 analogue, semaglutide, which is currently in Phase III clinical trials.

Novo Nordisk already manufacture and market Victoza for the treatment of type 2 diabetes but, if found successful and approved, semaglutide could offer once-weekly alternative for sufferers.

Related news

Show more

Related products

show more

Strategies to Achieve Successful Approval & Launch

Strategies to Achieve Successful Approval & Launch

Catalent Pharma Solutions | 03-Sep-2020 | Data Sheet

There are several key considerations to how companies should approach commercial-scale manufacturing that may aid the success of their biologic’s launch...

Single-Pass Tangential Flow Filtration

Single-Pass Tangential Flow Filtration

BioContinuum™ Platform - MilliporeSigma | 01-Aug-2020 | Application Note

Tangential flow filtration (TFF) is widely used in the biopharmaceutical industry for downstream processing applications. Typical TFF steps concentrate...

Follow us

Products

View more

Webinars